Novimmune and Sobi Get FDA Approval for First Ever Primary HLH Therapy

Edward Kim  |

~ First FDA-approved treatment for primary haemophagocytic lymphohistiocytosis (HLH) ~

Haemophagocytic lymphohistiocytosis (HLH) is a rare, life-threatening hyperinflammatory condition in which the body makes too many activated immune cells. HLH mostly affects infants and children, who usually inherit the disease; this is known as primary HLH. The condition can also occur in adults, who can acquire it through a variety of conditions including cancer and infections; this is known as acquired HLH. In patients with HLH, certain white blood cells attack the body's other blood cells. These abnormal cells collect in the spleen and liver, causing these organs to enlarge and malfunction, according to Johns Hopkins Medical Center. Other serious symptoms may include fever, cytopenia (decreased number of blood cells) and neurological abnormalities.

Novimmune, the privately held Swiss biopharmaceutical company, is developing antibody-based therapies for inflammatory diseases, immune-related disorders and cancer. The company discovered and developed an antibody called emapalumab that targets interferon gamma (IFNγ), a protein that, in normal quantities, is important to the regulation of immune functions. Abnormal levels of IFNγ, however, are associated with numerous autoinflammatory and autoimmune diseases including HLH, lupus, insulin-dependent diabetes and arthritis, among others. In July 2018, Novimmune sold the rights to emapalumab to Swedish Orphan Biovitrum, more commonly known as Sobi  (SWTUY), for SEK 3.65 billion (US$ 388 million) to be paid over nine annual installments.

The companies announced today that the FDA has approved emapalumab for the treatment of pediatric and adult patients with primary HLH with refractory, recurrent or progressive disease or intolerance to conventional HLH therapy. Emapalumab, to be marketed by Sobi as Gamifant, is the first approved therapy for primary HLH. Its targeted method of action represents a major advance over the current standard of care which can broadly involve chemotherapy, immunotherapy, steroids, antibiotics and antivirals. The approval was based on data from Novimmune's Phase 2/3 study which showed that 63% of primary HLH patients demonstrated an overall response at the end of treatment, and 70% of patients were able to proceed to stem cell transplantation.The FDA had previously granted Gamifant the multiple beneficial designations of Priority Review, Breakthrough Therapy and Orphan Drug.

Gamifant represents another win for Sobi, which announced last week that it acquired the US rights to Synagis (palivizumab) from AstraZeneca AZN. Synagis is the only approved respiratory syncytial virus (RSV) prophylaxis for high-risk infants. Gamifant and Synagis will complement Kineret (anakinra), Sobi's treatment for severe active rheumatoid arthritis in adults and neonatal-onset multisystem inflammatory disease (NOMID), to form a foundational immunology business.

The FDA approval of Gamifant marks an important milestone in Sobi's vision to bring transformative treatments to patients with a high medical need. Gamifant will add significant strength to Sobi's Immunology franchise, along with Kineret and the recent acquisition of the US rights to Synagis. We would like to acknowledge the excellent work done by Novimmune to develop and bring this important treatment to approval and Sobi will now focus on ensuring a successful commercialisation of Gamifant for the benefit of HLH patients in the US.

- Guido Oelkers, President and CEO, Sobi.
We are extremely glad to make a new medicine available for patients suffering from primary HLH. Gamifant is the first drug specifically targeted to neutralise IFNγ. We would like to extend our heartfelt thanks to the patients, families and the healthcare providers who participated in the emapalumab clinical study and whose efforts helped make today's approval possible. We would also like to thank the FDA for their continuous support during emapalumab development. Based on the clinical validation of this new target, additional clinical studies are ongoing or being planned with emapalumab in diseases for which IFNγ is considered pathogenic.

- Cristina de Min, Chief Medical Officer, Novimmune.

While Novimmune is a private company, there are numerous ways for investors to participate in the potential upside of the developmental pipeline of therapeutic antibodies as a result of the company's multi-pronged partnership strategy. In addition to Sobi, which trades most liquidly in Sweden with rather illiquid ADRs in the US, Novimmune also has agreements with Genentech, part of Roche  (RHHBY), TG Therapeutics TGTX, Shire  (SHPG), Tiziana Life Sciences  (TLSA) and LegoChem Biosciences (listed in Korea).

Primary HLH is a rare and life-threatening condition typically affecting children and this approval fills an unmet medical need for these patients. We are committed to continuing to expedite the development and review of therapies that offer meaningful treatment options for patients with rare conditions.

- Richard Pazdur, MD, Director, FDA’s Oncology Center of Excellence, and Acting Director, Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research.

Please email us at content@equities.com to see our Case Studies and Testimonials.

Please click here for information on our new trading platform.

Please click here to receive our free daily newsletter.

DISCLOSURE: The author has no positions or any beneficial interest in, and has received no compensation from, the companies mentioned in this article.


The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
SHPG Shire plc 172.48 2.82 1.66 1,981,511 Trade
TGTX TG Therapeutics Inc. 5.10 0.06 1.19 870,120 Trade
RHHBY Roche Holding Ltd ADR (Sponsored) 32.26 0.66 2.09 4,203,450
SWTUY Swedish Orphan Bio S/Adr 20.55 0.00 0.00 0
TLSA Tiziana Life Sciences plc 8.10 0.11 1.43 1,327 Trade

Comments

Level Headed at World Crypto Con - Steve Beauregard

Bloq.com CRO Steve Beauregard joins Jack Brewer at World Crypto Con.

Emerging Growth

CMX Gold & Silver Corp.

CMX Gold & Silver Corp is an exploration stage company. The Company is engaged in the acquisition, exploration and development of silver and copper/gold properties in the USA.